Blood microRNA markers to predict response to immunotherapy plus chemotherapy in extensive-stage small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

A prospective observational cohort at Shanghai Chest Hospital will enroll treatment-naïve patients with extensive-stage small cell lung cancer who are starting first-line immunochemotherapy (EP/EC plus immune checkpoint inhibitors). Pretreatment serum will be collected and small extracellular vesicle microRNAs (sEV miRNAs) will be sequenced and compared between patients who respond and those who do not. Differential expression analysis will be used to identify miRNA signatures associated with treatment response. Identified signatures could serve as noninvasive liquid biopsy biomarkers to help personalize treatment decisions in ES-SCLC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Requirements for patients enrolled in the project:

1. The pathological diagnosis of the patient is ESSCLC;
2. ECOG score 0 or 1；
3. The patient is receiving immunotherapy combined with chemotherapy for the first time and has no history of chemotherapy treatment;
4. Patients with complete clinical sample information who meet the inclusion requirements

Exclusion Criteria:

1. Patients whose pathological diagnosis does not meet the requirements;
2. Patients whose ECOG staging does not meet the requirements;
3. Patients with a history of chemotherapy, immunotherapy, or immunotherapy combined with chemotherapy;
4. Patients with incomplete clinical sample information and follow-up information;

Where it's running

• Shanghai Chest Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Wei Zhang, MD
• Email: zhwei2002@sjtu.edu.cn
• Phone: +86-021-62821990

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metronomic oral paclitaxel with PD-1/PD-L1 inhibitor maintenance in advanced lung cancer

  This trial tests whether taking low, regular doses of oral paclitaxel plus a PD-1 or PD-L1 inhibitor as maintenance therapy can help people with advanced sqNSCLC or ES-SCLC who did not progress after first-line chemo-immunotherapy.

  Recruiting Phase 4 Anhui Provincial Cancer Hospital · Hefei, Anhui · NCT07744698

• DJI136 CAR-T therapy for extensive-stage small cell lung cancer

  Researchers are testing DJI136, a CAR-T cell therapy, to see if it can help adults with extensive-stage small cell lung cancer who have already tried standard treatments.

  Recruiting at 7 sites Phase 1/2 Novartis · Lexington, Kentucky and 6 other locations · NCT07564401

• Obrixtamig with atezolizumab, carboplatin, and etoposide for advanced small cell lung cancer

  This trial will test whether adding obrixtamig to atezolizumab plus carboplatin and etoposide helps people with extensive-stage small cell lung cancer live longer.

  Recruiting at 166 sites Phase 3 Boehringer Ingelheim · Mobile, Alabama and 241 other locations · NCT07472517

• Tislelizumab with chemotherapy followed by chest consolidation radiotherapy as first-line treatment for extensive-stage small cell lung cancer

  This trial will test whether adding the immunotherapy drug tislelizumab to standard chemotherapy followed by chest radiation helps people newly diagnosed with extensive-stage small cell lung cancer.

  Recruiting Phase 2 Chongqing University Cancer Hospital · Chongqing, Chongqing Municipality · NCT07425795

• Sacituzumab govitecan with atezolizumab or durvalumab as maintenance for extensive-stage small cell lung cancer

  This study tests whether adding sacituzumab govitecan to ongoing atezolizumab or durvalumab can better control tumors in adults with extensive-stage small cell lung cancer after initial platinum-based chemotherapy.

  Recruiting Phase 2 Henry Ford Health System · Detroit, Michigan · NCT07339059

• Ivonescimab combinations for first-line extensive-stage small cell lung cancer

  This test tries whether adding AK117 or cadonilimab to ivonescimab plus chemotherapy helps adults newly diagnosed with extensive-stage small cell lung cancer.

  Recruiting at 2 sites Phase 2 Akeso · Beijing, Beijing Municipality and 2 other locations · NCT07245446

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.